Maintenance notice in CEST time zone (1:00 - 3:30 AM May 17, 2026): Our website is scheduled for maintenance. The website will be available, but some functions may experience errors. We appreciate your patience and understanding.
Published TCIMAIL newest issue No.201
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 161058-83-9 | Product Number: N0958
NU 2058
×
Purity: >98.0%(HPLC)(qNMR)
Synonyms:
- O-Cyclohexylmethylguanine
Product Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
Shipping Information
|
|---|---|---|---|---|---|
| 20MG |
€ 47,00
|
1 | 26 |
|
|
| 100MG |
€ 161,00
|
1 | 30 |
|
* Stock available in Belgium: Shipment on the same day
* Stock available in Japan: Please check the Shipping Simulation for estimated shipments. (excludes regulated items and dry ice shipments)
| Product Number | N0958 |
Purity / Analysis Method 
|
>98.0%(HPLC)(qNMR) |
| Molecular Formula / Molecular Weight | C__1__2H__1__7N__5O = 247.30 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature
|
Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| CAS RN | 161058-83-9 |
| Reaxys Registry Number | 7645499 |
| PubChem Substance ID | 253661766 |
| MDL Number | MFCD05664734 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(qNMR) | min. 98.0 % |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 199 °C |
| Maximum Absorption Wavelength | 281 nm (MeOH) |
GHS
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H315 : Causes skin irritation. H319 : Causes serious eye irritation. |
| Precautionary Statements | P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ eye protection/ face protection. P302 + P352 : IF ON SKIN: Wash with plenty of water. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P362 + P364 : Take off contaminated clothing and wash it before reuse. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. |
Related Laws:
Transport Information:
| HS Number | 2933599590 |
Application
サイクリン依存性キナーゼ阻害因子(阻害剤)，NU2058
O-Cyclohexylmethylguanine (NU2058) is an ATP competitive cyclin-dependent kinases (CDK1 and CDK2) inhibitor which inhibits the function of the kinases. Cyclin-dependent kinases (CDKs) are a group of protein kinases that are activated by the formation of a complex with a cyclin and are involved in the regulation of the cell cycle. Aberrant control of CDKs is a central feature of the molecular pathology of cancer cell, and in recent years CDKs are targeted for anti-cancer drugs.
References
- Identification of Novel Purine and Pyrimidine Cyclin-Dependent Kinase Inhibitors with Distinct Molecular Interactions and Tumor Cell Growth Inhibition Profiles
- Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor
- Cyclin-dependent kinase modulators studied at the NCI: Pre-clinical and clinical studies (a review)
- N2-Substituted O6-Cyclohexylmethylguanine Derivatives: Potent Inhibitors of Cyclin-Dependent Kinases 1 and 2
- Insights into the Structural Basis of N2 and O6 Substituted Guanine Derivatives as Cyclin-Dependent Kinase 2 (CDK2) Inhibitors: Prediction of the Binding Modes and Potency of the inhibitors by Docking and ONIOM Calculations
PubMed Literature
Product Articles
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.